ArticleAntimicrobial resistance and infection control2025
The impact of carbapenem-resistant infections in intensive care units: focus on non-fermenting gram-negative bacilli and survival analysis.
Article in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Wet Environmental Surveillance of Antimicrobial Resistance Genes in High-Risk Hospital Units.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical Severity and Organ Dysfunction as Drivers of Mortality in Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Six Years ofAntibiotics (Basel, Switzerland) · 2026Article
- Integrated Phenotypic, Proteomic (MALDI-TOF MS), and Genomic (WGS) Investigation of a Prolonged Hospital Outbreak ofAntibiotics (Basel, Switzerland) · 2026Article
- Predictors of clinical outcomes in Chinese patients with carbapenem-resistant Gram-negative bacterial infections receiving colistimethate sodium: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCarbapenem-resistant non-fermenting Gram-negative bacilli (CR Nf-GNB) infections present a significant challenge in intensive care units (ICUs). Despite being recognized as a significant clinical problem, comprehensive studies on the impact of CR Nf-GNB infections on patient morbidity and mortality remained limited.
methodsUsing data from the REA-REZO surveillance network, which includes 206 adult ICUs in France, we analysed patients admitted between 2016 and 2022 who developed healthcare-associated infections caused either by CR Nf-GNB or carbapenem-susceptible (CS) Nf-GNB. Propensity scores were calculated using a logistic regression model including relevant covariates, and CR and CS Nf-GNB patients were matched 1:1. The primary outcome was 30-day ICU survival, and secondary outcomes included 30-day reinfection (different pathogen) and relapse (same pathogen) rates.
resultsAmong the 17,527 Nf-GNB infections, 3,171 were caused by CR strains. After matching, 1,498 patients were included in each group. CR Nf-GNB infections were independently associated with a significantly higher risk of death (adjusted sub-Hazard Ratio [sHR] 1.57 [95% CI, 1.40-1.76]) and increased reinfection rates (sHR 1.23 [95% CI, 1.01-1.50]) compared to CS Nf-GNB infections. CR infections also showed a higher proportion of reinfections with multidrug-resistant organisms.
conclusionCR Nf-GNB infections in ICU patients significantly increased mortality, and the risk of reinfection. CR Nf-GNB was not associated with a higher risk of relapse. These findings underscore the importance of targeted infection control measures and novel treatment strategies to manage CR Nf-GNB in critical care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.